Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) FCF Margin (2020 - 2025)

Tango Therapeutics has reported FCF Margin over the past 6 years, most recently at 57.46% for Q3 2025.

  • Quarterly results put FCF Margin at 57.46% for Q3 2025, up 23121.0% from a year ago — trailing twelve months through Dec 2025 was 224.31% (up 9006.0% YoY), and the annual figure for FY2025 was 224.31%, up 9007.0%.
  • FCF Margin for Q3 2025 was 57.46% at Tango Therapeutics, up from 1154.48% in the prior quarter.
  • Over the last five years, FCF Margin for TNGX hit a ceiling of 42.99% in Q2 2021 and a floor of 1154.48% in Q2 2025.
  • Median FCF Margin over the past 5 years was 317.43% (2021), compared with a mean of 432.53%.
  • Biggest five-year swings in FCF Margin: soared 42406bps in 2023 and later tumbled -103409bps in 2025.
  • Tango Therapeutics' FCF Margin stood at 291.1% in 2021, then tumbled by -88bps to 546.03% in 2022, then grew by 12bps to 482.51% in 2023, then tumbled by -85bps to 893.15% in 2024, then surged by 94bps to 57.46% in 2025.
  • The last three reported values for FCF Margin were 57.46% (Q3 2025), 1154.48% (Q2 2025), and 774.26% (Q1 2025) per Business Quant data.